We chose the SCC74A and SCC74B cell lines for this study because previous work demonstrated elevated HER2 and EGFR in the more-aggressive SCC74B cell line (derived from a 1-year recurrence) compared to SCC74A cells (derived from the primary tumor at the same site).20 This evidence concerns the gene EGFR and neoplasm.